Lepu Medical
Lepu Medical Technology (Beijing) Co., Ltd. was established in 1999. It is specialized in developing, manufacturing and marketing the high-tech medical devices and equipment. Today, Lepu Medical has grown into a global leading group company in the fields of cardiovascular interventions, structural heart diseases, cardiac rhythm management, anesthesia and critical care, in vitro diagnostics and general surgery with products include coronary stents, dilatation balloon catheters, interventional accessories, occlusion devices, mechanical heart valves, electrophysiology catheters, pacemakers, in vitro diagnostic equipment and biomarkers, DSA systems and surgical staplers. In 2009, Lepu Medical successfully went public, and listed on ChiNext Shenzhen Stock Exchange Market (stock code: 300003).
Inspirna (formerly Rgenix) is a clinical-stage biopharmaceutical company developing first-in-class/best-in-class drug candidates that target critical cancer drivers. Our discovery platform leverages RNA biology to discover novel RNA dysregulated cancer drivers that can be targeted by small molecules and biologics. Clinical programs are first-in-class oral small molecules in development for patients with RAS mutant CRC (RGX-202; Phase 1b) as well as SCLC and NSCLC (RGX-104; Phase 1b/2)
Lepu Bio they have developed an oncology-focused pipeline of drug candidates, including ADCs, oncolytic virus drugs, and immunotherapies at clinical and pre-clinical stages.
Thai flute rookie network as the Internet industry, providing people with more clean living, so you every day: clean as new! Thai flute network using advanced Internet technology, the use of the washing plant type, to provide users with fast, convenient and high-quality cleaning services. Whether it is in the Thai flute net tops, culottes, or shoes, bags, leather, or home sofa cushion, carpet, or car seat, and we stop to help you clean and care as new.
Inspirna (formerly Rgenix) is a clinical-stage biopharmaceutical company developing first-in-class/best-in-class drug candidates that target critical cancer drivers. Our discovery platform leverages RNA biology to discover novel RNA dysregulated cancer drivers that can be targeted by small molecules and biologics. Clinical programs are first-in-class oral small molecules in development for patients with RAS mutant CRC (RGX-202; Phase 1b) as well as SCLC and NSCLC (RGX-104; Phase 1b/2)
Youjiali is an artificial intelligence ECG-assisted analysis technology and mobile ECG medical equipment. They provide complete health and medical service ecosystem.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.